首页> 外文OA文献 >Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

【2h】

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

机译：乳腺癌临床前模型的药代动力学与药效分析，评估其雌激素受体-α降解活性在抗肿瘤功效中的重要性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Suzanne E. Wardell; Alexander P. Yllanes; Christina A. Chao; Yeeun Bae; Kaitlyn J. Andreano; Taylor K. Desautels; Kendall A. Heetderks; Jeremy T. Blitzer; John D. Norris; Donald P. McDonnell;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells [J] . MAMORU NUKATSUKA, HITOSHI SAITO, SHINZABURO NOGUCHI, In vivo. . 2019,第5期

机译：雌激素下调的氟维斯特能增强氟嘧啶在雌激素反应性MCF-7人乳腺癌细胞中的抗肿瘤活性。
2. Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：口服选择性雌激素受体降解剂AZD9496表现出临床前模型对雌激素受体降解，激动性和抗肿瘤作用的普发生儿的特异性差异
3. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models [J] . Bihani Teeru, Patel Hitisha K., Arlt Heike, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第16期

机译：选择性雌激素受体降解剂（SERD），具有抗肿瘤活性，在多er +乳腺癌患者衍生的异种移植模型中具有抗肿瘤活性
4. Study on Molecular Docking of Red Betel (Piper Crocatum Ruiz Pav.) Active Compound and Tamoxifen Drug as an Inhibitor of Estrogen Receptor-α (ER-α) that Plays a Role in Breast Cancer [C] . Siti Imroatul Maslikah, Sri Rahayu Lestari, Nursasi Handayani, International Conference on Life Sciences and Technology . 2020

机译：红色槟榔（吹笛茶叶ruiz＆pav.）活性化合物和三氧化物药物作为发挥乳腺癌作用的雌激素受体-α（ER-α）抑制剂的研究
5. Mechanisms of Action and Efficacy Modulation of Novel Retinoic Acid Metabolism Blocking Agent (RAMBA) VN/12-1 in Estrogen Receptor-α Negative Breast Cancer Model Systems: Targeting Autophagy [D] . Godbole, Abhijit Moreshwar 2011

机译：新型视黄酸代谢阻断剂（RAMBA）VN / 12-1在雌激素受体-α阴性乳腺癌模型系统中的作用和功效调节机制：靶向自噬
6. RAD1901: a novel orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models [O] . Fiona Garner, Maysoun Shomali, Dotty Paquin, -1

机译：RAD1901：一种新型的可口服生物利用的选择性雌激素受体降解剂在乳腺癌异种移植模型中显示出抗肿瘤活性
7. Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy [O] . Suzanne E. Wardell, Alexander P. Yllanes, Christina A. Chao, 2019

机译：校正：乳腺癌临床前模型中氟斯特语的药代动力学和药物动力学分析，评估其雌激素受体-α降解活性在抗肿瘤功效中的重要性

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

著录项

引文网络

相似文献

相关主题

期刊订阅